Longevity Scientist Plans Human Trials for Age-Reversal Drug in XPrize Competition
Harvard biologist David Sinclair is preparing human trials for an oral "reprogramming" drug aimed at reversing aging. These tests are part of a $101 million XPrize competition seeking to demonstrate a 10-year age reduction through improved biological functions within one year.
Key points
- Longevity scientist David Sinclair plans to test an oral "reprogramming" drug on human volunteers.
- The trials are part of a $101 million XPrize Foundation competition.
- The competition aims to achieve a 10-year (or greater) relative age reduction in participants.
- Success will be measured by improvements in immune, cognitive, and muscle function after one year of treatment.
- The technology is based on chemical reprogramming, which resets epigenetic marks on DNA to potentially reverse cellular aging.
Harvard Medical School biologist David Sinclair is set to initiate human trials for a novel "reprogramming" drug, an effort aimed at achieving whole-body rejuvenation. The research is being conducted in conjunction with the XPrize Foundation's $101 million competition, which challenges teams to demonstrate significant age reversal in humans.
Sinclair's proposed trials involve administering an oral drug mixture to volunteers. The primary goal is to gather evidence for age restoration in humans, measured by key biological markers. Specifically, the XPrize competition seeks to identify treatments that can restore a person to an earlier apparent age, evidenced by substantial improvements in immune, cognitive, and muscle functions.
The grand prize of the competition will be awarded to any team that can prove a relative age reduction of 10 years or more after a single year of treatment. This approach leverages the concept of chemical reprogramming, a technology inspired by the discovery that certain genes can revert adult cells to a stem-cell-like state. The underlying theory suggests that resetting "epigenetic marks" on DNA can influence cellular metabolism and identity, potentially counteracting the aging process.
Sources
The WireByte editorial team synthesises technology news from multiple primary sources, verifies the facts, and links every source. Articles are produced with AI assistance and reviewed under our editorial policy.